Cardiovascular drugs are widely used for treating various heart
related dysfunction. With increasing number of cardiovascular
diseases across the globe is the major driving factor for the growth
of the cardiovascular diseases. According to the study conducted by
Global Burden of Diseases estimate that the death rate due to CVD is
235 per 100000 in global population. According to WHO, cardiovascular
diseases account for 31% deaths globally which is approximately 17.7
million individuals. Out of these 80% of the CVD deaths are due to
stroke and heart attacks. Factors such as sedentary lifestyle,
excess consumption of alcohol, stress, unhealthy eating habits,
smoking are all factors responsible for the increase in the number of
cardiovascular disorders among young population too.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33281
The global cardiovascular drugs market report comprises an elaborate
executive summary, which includes a market snapshot that provides
information about various segments of the market. It also provides
information and data analysis of the global market with respect to
the segments based on drug class, indication, distribution channel
and geography. A detailed qualitative analysis of drivers and
restraints of the market and opportunities has been provided in the
market overview section. In addition, the section comprises
competitive matrix and company profiles with business overview to
understand the competitive landscape in the market. This section of
the report also provides market attractiveness analysis, by geography
and market share analysis by key players, thus presenting a thorough
analysis of the overall competitive scenario in the global
cardiovascular drugs market.
Based on drug class the global cardiovascular drugs market is
segmented into renin-angiotensin system blockers, beta blockers,
diuretics, anti-clotting agents (anti-coagulants and platelet
aggregation inhibitors), antihyperlipidemics, other antihypertensive,
calcium channel blockers and others. The renin-angiotensin system
blockers segment is further classified into ACE inhibitors and
angiotensin receptor blockers and the anti-clotting agents segment is
further segmented into anti-coagulants and platelet aggregation
inhibitors. The drug class segments have been analyzed based on
incidence of diseases, awareness regarding early diagnosis and
presence of key players in the region. The market size and forecast
for each of these segments have been provided for the period from
2015 to 2025, along with their respective CAGRs for the forecast
period from 2017 to 2025, considering 2016 as the base year.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33281
According to indication the global cardiovascular drugs market is
segmented into hypertension, hyperlipidemia, coronary artery
diseases, peripheral artery disease, arrhythmia and others. The
market size and forecast for each of these segments have been
provided for the period from 2015 to 2025, along with their
respective CAGRs for the forecast period from 2017 to 2025,
considering 2016 as the base year.
Geographically, the global cardiovascular drugs market has been
categorized into five major regions and the key countries in the
respective region: North America (the U.S., Canada), Europe (the
U.K., Germany, France, Italy, Spain and Rest of Europe), Asia Pacific
(China, Japan, India, Australia & New Zealand and Rest of Asia
Pacific), Latin America (Brazil, Mexico and Rest of Latin America)
and Middle East & Africa (South Africa, GCC Region, Israel and
Rest of Middle East & Africa). The market size and forecast for
each of these regions and the mentioned countries have been provided
for the period from 2015 to 2025, along with their respective CAGRs
for the forecast period from 2017 to 2025, considering 2016 as the
base year. The research study also covers the competitive scenario in
these regions.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=33281
The report also profiles the major players in the market and provides
various attributes such as company overview, financial overview,
product portfolio, business strategies, and recent developments.
Major companies profiled in the cardiovascular drugs market are
AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc.,
Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim
GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead
Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli
Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceuticals
Company Limited and others.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment